Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

MediWound Ltd.

Begin the MWPC005 phase I/II basal cell carcinoma study in the United States

Delivered after the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
22 Feb 2021
Due
30 Jun 2021
Delivered
July 2021
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“is preparing to initiate this study in the United States in the second quarter of 2021”
  • SourceMediWound Ltd. Form 6-K press release, 2021-02-22
  • FilingSEC filing index
  • Deadline as statedin the second quarter of 2021
  • Deadline used30 Jun 2021, the last day of the stated period
  • TypeProject
  • Permanent referenceKI-C-2021-MDWD-024154
    Cite as https://keptindex.org/c/KI-C-2021-MDWD-024154/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company initiated the U.S. phase I/II MW005 study in July 2021, after the end-of-June 2021 deadline; the July 26, 2021 press release announced the initiation.

  • A
    MediWound Ltd. 6-K filed 2021-07-26 Regulatory filing · published 26 Jul 2021 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “today announced initiation of its phase I/II study of MW005 for the treatment of low-risk Basal Cell Carcinoma (BCC).” ✓ confirmed on the page
  • A
    MediWound Ltd. 20-F filed 2022-03-17 Regulatory filing · published 17 Mar 2022 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “In July 2021, we initiated a U.S. phase I/II study of MW005 for the treatment of low-risk basal cell carcinoma (BCC).” ✓ confirmed on the page

Checked 26 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Project other
Indicative materiality
Low rules
Action
Begin
Deliverable
MWPC005 phase I/II basal cell carcinoma study initiation
Where
United States
In the company’s control
Medium
Specificity
High
Depends on
Regulatory

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you MediWound Ltd.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-MDWD-024154 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.